Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeted protein degradation: from mechanisms to clinic
Jonathan M. Tsai, Radosław P. Nowak, Benjamin L. Ebert, et al.
Nature Reviews Molecular Cell Biology (2024) Vol. 25, Iss. 9, pp. 740-757
Closed Access | Times Cited: 87

Showing 26-50 of 87 citing articles:

Targeted degradation of GOLM1 by CC-885 via CRL4-CRBN E3 ligase inhibits hepatocellular carcinoma progression
Jingliang He, Jingli Guo, Shunfang Liu, et al.
Cellular Signalling (2025), pp. 111665-111665
Closed Access
Design, Synthesis, and Biological Evaluation of Novel BTK-targeting Proteolysis Targeting Chimeras (PROTACs) with Enhanced Pharmacokinetic Properties
Ying‐Hung Lin, Jing Liu, Xiaohe Tian, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117420-117420
Closed Access
Targeted degradation of CDK4/6 by LA-CB1 inhibits EMT and suppresses tumor growth in orthotopic breast cancer
Jingliang He, Shunfang Liu, Siyi Zhang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Action and therapeutic targets of folliculin interacting protein 1: a novel signaling mechanism in redox regulation
Qingzhi Ran, Aoshuang Li, Bo Yao, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 13
Open Access
Smartphone-Manipulated Mild-Temperature Photothermal Control of the TfR-LYTAC Platform for Tumor Treatment
Chengyong Shi, Ling-Yan Su, Wen Xu, et al.
Nano Letters (2025)
Closed Access
Diversity Synthesis Using Glutarimides as Rhodium Carbene Precursors in Enantioselective C–H Functionalization and Cyclopropanation
William F. Tracy, Jack C. Sharland, Duc Ly, et al.
Journal of the American Chemical Society (2025)
Open Access
Discovery of Novel Rigid STING PROTAC Degraders as Potential Therapeutics for Acute Kidney Injury
Rui Ma, Renquan Fu, Yifan Wang, et al.
European Journal of Medicinal Chemistry (2025), pp. 117539-117539
Closed Access
Can we develop effective direct or indirect inhibitors of transcription factors? On the clinical evolution of protein degraders for multiple myeloma therapy
Rajeshwari Meli, Osman Aksoy, Sonia Vallet, et al.
Expert Opinion on Therapeutic Targets (2025)
Closed Access
Advancements in Proteolysis Targeting Chimeras for Targeted Therapeutic Strategies in Alzheimer’s Disease
Qiuzhi Zhou, Weixia Wang, Chunchu Deng
Molecular Neurobiology (2025)
Open Access
Multivalent DNA lysosome-targeting chimaera for targeted protein degradation and inhibition of c-Met signaling pathways
Xinhuan Chen, Mengmeng Ji, Xue Bai, et al.
Chemical Engineering Journal (2025), pp. 161974-161974
Closed Access
Structural mimicry of UM171 and neomorphic cancer mutants co-opts E3 ligase KBTBD4 for HDAC1/2 recruitment
Zhuoyao Chen, Gamma Chi, Timea Baló, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Harnessing the SPOP E3 Ubiquitin Ligase via a Bridged Proteolysis Targeting Chimera (PROTAC) Strategy for Targeted Protein Degradation
Zhijie Deng, Jerrel L. Catlett, Youngeun Lee, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Targeted MYC2 stabilization confers citrus Huanglongbing resistance
Pingzhi Zhao, Huan Yang, Yanwei Sun, et al.
Science (2025) Vol. 388, Iss. 6743, pp. 191-198
Closed Access
Manipulation of targeted protein degradation in plant biology
Marcela Rojas‐Pierce, Sebastian Y. Bednarek
Biochemical Society Transactions (2025) Vol. 53, Iss. 02
Open Access
USP28-Based Deubiquitinase-Targeting Chimeras for Cancer Treatment
Zhen Wang, C. D. Qian, Yan Xiong, et al.
Journal of the American Chemical Society (2025)
Closed Access
LAPTM5 Confers the Resistance to Venetoclax via Promoting the Autophagosome‐Lysosome Fusion in Multiple Myeloma
Yuxiang Li, Jing Bai, Dan Liu, et al.
Journal of Cellular and Molecular Medicine (2025) Vol. 29, Iss. 1
Open Access
DNA Tetrahedron-Driven Multivalent Proteolysis-Targeting Chimeras: Enhancing Protein Degradation Efficiency and Tumor Targeting
Shiqing Li, Tao Zeng, Zhixing Wu, et al.
Journal of the American Chemical Society (2025)
Closed Access
Multifaceted roles of UFMylation in health and disease
R. Wang, Li Lin, Jun Zhou, et al.
Acta Pharmacologica Sinica (2025)
Closed Access
Identification of actionable targeted protein degradation effector sites through Site-specific Ligand Incorporation-induced Proximity (SLIP)
Zhangping Xiao, Efthymios Spyridon Gavriil, Fangyuan Cao, et al.
(2025)
Open Access
Computational approaches to aid PROTAC drug discovery
Sohini Chakraborti, Kirsten McAulay
Elsevier eBooks (2025)
Closed Access
Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions
Rajamanikkam Kamaraj, Subhrojyoti Ghosh, Souvadra Das, et al.
Bioconjugate Chemistry (2024) Vol. 35, Iss. 8, pp. 1089-1115
Open Access | Times Cited: 3
New therapies on the horizon: Targeted protein degradation in neuroscience
James A Gregory, Christopher M. Hickey, Juan D. Chavez, et al.
Cell chemical biology (2024) Vol. 31, Iss. 9, pp. 1688-1698
Open Access | Times Cited: 3
Next steps for targeted protein degradation
Mackenzie W. Krone, Craig M. Crews
Cell chemical biology (2024)
Closed Access | Times Cited: 3
How kelch domain-containing protein 3 distinguishes between the C-end degron of herpesviral protein UL49.5 and its mutants – Insights from molecular dynamics
Magdalena J. Ślusarz
Bioorganic & Medicinal Chemistry (2024) Vol. 109, pp. 117795-117795
Closed Access | Times Cited: 2
Structural Biology in Drug Discovery and Development: Call for Papers
David E. Heppner, Simone V. Bigi-Botterill, Andrew P. Riley, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 15, pp. 12461-12462
Closed Access | Times Cited: 2

Scroll to top